Search

Low-dose Bevacizumab Plus Adebrelimab Combined With TACE-HAIC for Unresectable HCC

A single-arm Phase 2 clinical trial (NCT07543783) has been registered as of April 22, 2026, enrolling 38 participants with unresectable hepatocellular carcinoma (HCC) to evaluate the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic arterial infusion chemotherapy (HAIC) using the FOLFOX regimen as first-line treatment. The study, sponsored by the Third Affiliated Hospital of Sun Yat-sen University, uses Simon's two-stage optimal design (alpha=0.05, power=0.8) with objective response rate (ORR) per RECIST v1.1 as the primary endpoint.